-
2024-511508-18-00
9
2026-01-05
Chronic graft versus host disease.
-
2022-503070-36-00
5
2025-12-23
Group B streptococcus (GBS) disease
-
2024-515172-12-00
4
2025-12-23
Epidermolysis Bullosa
-
2025-522680-14-00
2
2025-12-23
Chronic Graft-versus-Host Disease
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-519745-30-01
9
2025-12-19
Immune Thrombocytopenia (ITP)
-
2025-520742-29-00
5
2025-12-19
Low-risk renal transplant patients
-
2025-521003-52-00
9
2025-12-19
HER2 Expressing Advanced Breast Cancer
-
2025-521155-23-00
4
2025-12-19
Pulmonary Arterial Hypertension
-
2025-521692-31-00
5
2025-12-19
Chronic Primary Immune Thrombocytopenia
-
2025-521843-19-00
4
2025-12-19
IDH1/2-mutated, ATRX-mutated and p53-mutated astrocytoma
-
2024-512298-28-00
11
2025-12-18
Neovascular age-related macular degeneration
-
2024-518288-37-00
3
2025-12-18
Lupus Nephritis
-
2025-521128-31-00
9
2025-12-18
Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
-
2025-522203-23-00
7
2025-12-18
Advanced Solid Tumors
-
2024-513008-32-00
4
2025-12-17
Adenocarcinoma of the gastroesophageal junction
-
2024-517653-27-00
4
2025-12-17
Prostate Cancer
-
2024-516148-24-00
5
2025-12-16
Down syndrome
-
2025-520825-19-00
5
2025-12-16
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as
Ber
-
2025-522517-35-00
7
2025-12-16
Patients with advanced/metastatic tumors with head and neck squamous c
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2025-523009-14-00
4
2025-12-16
Bronchiectasis with chronic pseudomonas aeruginosa colonization
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-522395-92-00
5
2025-12-15
metastatic oeso-gastric adenocarcinoma